Mission        Dr. Arthur Heffter       Board of Directors       Psilocybin

Image of Heffter Home Page Background featuring a gray backdrop and a smiling womanImage of Heffter Research logo

HEFFTER

RESEARCH INSTITUTE

Advancing studies on psilocybin for treatment of addictions and other
mental disorders, with the highest standards of scientific research

LEARN MORE

Image of the University of Zurich logoYale logo
Image of Heffter Home Page Background featuring a gray backdrop and a smiling woman

Image of Heffter Research logo

HEFFTER

RESEARCH INSTITUTE

Advancing studies on psilocybin for treatment
of addictions and other mental disorders,
with the highest standards of scientific research.

LEARN MORE

Image of the University of Zurich logoYale logo

MISSION

 

The Heffter Research Institute promotes research of the highest scientific quality with the classic hallucinogens and related compounds (sometimes called psychedelics) in order to contribute to a greater understanding of the mind leading to the improvement of the human condition, and to alleviate suffering.

THE HEFFTER RESEARCH INSTITUTE

 

The Heffter Research Institute was incorporated in New Mexico in 1993 as a non-profit, 501(c)(3) scientific organization. Since its inception, Heffter has been helping to design, review, and fund the leading studies on psilocybin at prominent research institutions in the US and Europe. Our research has explored psilocybin for the treatment of cancer-related distress and addiction, for understanding the relationship between the psychedelic experience and spirituality, and for basic science research into the physiology of brain activity, cognition, and behavior. The Heffter Institute believes that psychedelics have great, unexplored potential that requires independently funded scientific research to find their best uses in medical treatment. We are not an endowed foundation, and so there is a continuous need for funding to support this critical research.

 

Since the founding of the Heffter Research Institute in 1993, Heffter-affiliated researchers account for 63% (17 of 27) of top-cited articles on classic psychedelics.

 

It is the policy of the Institute that none of its grants may be spent for indirect costs at institutions.

Dr. Arthur Heffter

 

The Institute is named in honor of Dr. Arthur Heffter,
a turn-of-the-century German research pharmacologist, who was the first scientist to study, systematically, a naturally-occurring hallucinogen, publishing his work in 1897.

Black and white image of Dr. Arthur Heffter

OUR
BOARD OF DIRECTORS

Click a Photo or Name to View Biography.

Dr. George Greer

GEORGE R. GREER, MD
PRESIDENT, CO-FOUNDER

Color image of Heffter President David Nichols

DAVID E. NICHOLS, PhD
VICE-PRESIDENT, FOUNDER

Mark Geyer, Heffter's Director of Behavioral Pharmacology

MARK A. GEYER, PhD
TREASURER, CO-FOUNDER

STEVEN GRANT, PhD
DIRECTOR OF RESEARCH

KATRIN PRELLER, PhD
CHIEF SCIENTIST

ROLAND R. GRIFFITHS, PhD
BOARD MEMBER, DECEASED

Color image of Charles Grob, Heffter's Director of Clinical Research

CHARLES S. GROB, MD
CO-FOUNDER

JANIS PHELPS, PhD
BOARD MEMBER

T. CODY SWIFT, MA
BOARD MEMBER

Color image of Heffter Board Member Carey Turnbull

CAREY TURNBULL
BOARD MEMBER

CLAUDIA TURNBULL
BOARD MEMBER

PSILOCYBIN

 

Psilocybin is a psychoactive substance that acts on serotonin brain receptors resulting in changes of perception, cognition, and emotion. In medicine, psilocybin and similar substances such as mescaline and dimethyltryptamine (DMT) are often called psychedelics or “hallucinogens,” though they usually do not cause actual hallucinations.

 

Psilocybin occurs naturally in certain mushrooms (also referred to as “magic mushrooms”). For possibly thousands of years, mushrooms containing psilocybin have been used in religious and healing practices to induce mystical or spiritual states of consciousness. Under clinical supervision, psilocybin has shown to produce important insights and memories, greater access to emotions, and help provide perspective around life meaning, which can all contribute to relief from anxiety and addictive patterns.

Image of psilocybin molecule

The Psilocybin Session

 

All Heffter sponsored trials with psilocybin follow a similar protocol to ensure safety for the participant and efficacy of their treatment. Prior to enrollment, participants are screened for current and prior history of serious mental illness to gauge appropriateness of the treatment. Once enrolled, participants spend several weeks prior to their psilocybin session developing close rapport and trust with the study team and their two guides and to establish an intimate understanding of the participant’s psychological history and treatment goals. Psilocybin is administered in a specially designed living-room style room, decorated with artwork, comfortable furniture, and soft lighting. It specifically avoids a “laboratory” look and feel. Participants take a single capsule of psilocybin administered by their two male and female study guides who are present for interpersonal support throughout the entire session. During most of the 8-hour session, participants are encouraged to lie on the couch, wearing eyeshades and listening to supportive music through headphones, and thus much of the time in which psilocybin is in effect will be spent in quiet internal reflection. Follow-up sessions in the days and months after the psilocybin dosing will help participants to further integrate aspects of their psilocybin experience. Medical support is available on-site.

How long will the effect of psilocybin last?

 

While the session itself may last up to eight hours, research has shown that even a one-time experience with psilocybin in a clinical setting can reliably occasion dramatic shifts in consciousness and awareness that may lead to long-term, sustained improvement in anxiety, depression, as well as one’s sense of overall wellbeing and spiritual connection.

 

Psilocybin is a powerful medicine and it is Heffter’s position that the positive effects found in research to date are achieved only when prescribed by a doctor and used in a therapeutic setting. Safety has not been demonstrated for psilocybin when used outside of a structured clinical or laboratory setting and we strongly caution against recreational use of psilocybin because of potential adverse psychological reactions.